Skip to main content
. Author manuscript; available in PMC: 2009 Aug 1.
Published in final edited form as: Mol Ther. 2008 Jun 10;16(8):1382–1391. doi: 10.1038/mt.2008.112

Figure 6. Impact of OV-induced CYR61 on glioma biology and oncolysis.

Figure 6

(a) Images of individual angioreactors containing HSVQ-treated (top) and phosphate-buffered saline (PBS)-treated LN229 glioma cells at the time of harvesting. Briefly, angioreactors filled with LN229 glioma cells treated with either PBS or HSVQ (n = 9/group) in the presence or absence of Cilengitide (30 ng/angioreactor) were implanted subcutaneously in athymic nude mice. Fifteen days after implantation the angioreactors were harvested and analyzed visually for blood vessels that had developed into the tubes. The presence of visually obvious initiation of blood vessels into six of the nine HSVQ-treated angioreactors and in three of the nine PBS-treated angioreactors are indicated by arrow heads. (b) Quantification of hemoglobin (Hb) in angioreactors: The contents of the individual angioreactors were isolated and the amount of Hb in each tube was quantified. Note the significant reduction in Hb content of angioreactors treated with HSVQ in the presence of Cilengitide (P ≤ 0.036).